文献速递肾癌与肾肿瘤

透明细胞肾细胞癌中不同肿瘤大小间突变的差异

Differences in mutations across tumour sizes in clear-cell renal cell carcinoma.
PubMed 文献 · BJU Int · 2024-09-12

研究评估1039例透明细胞肾细胞癌中关键突变随肿瘤大小的分布,并分析≤7 cm肿瘤中侵袭性突变的预后影响。每增加1 cm,SETD2、BAP1和CDKN2A缺失的OR分别为1.09、1.10和1.19(P<0.001);在≤7 cm肿瘤中,SETD2和CDKN2A缺失与转移相关(OR 3.86和3.84,P<0.05),CDKN2A缺失与更差总生存相关(HR 2.19,P=0.03),SETD2与更差无复发生存相关(HR 2.00,P=0.03)。

要点

  • 肿瘤大小每增加1 cm,SETD2、BAP1和CDKN2A缺失的OR分别为1.09、1.10和1.19(P<0.001)。
  • ≤7 cm肿瘤中,SETD2和CDKN2A缺失与转移相关(OR 3.86和3.84,P<0.05)。
  • ≤7 cm肿瘤中,CDKN2A缺失与更差总生存相关(HR 2.19,P=0.03)。

核心结论

  • 大与小的透明细胞肾细胞癌在基因组上不同,SETD2、BAP1和CDKN2A缺失在小型透明细胞肾细胞癌中少见而在较大肿瘤中更常见。
  • 然而在≤7 cm的肿瘤中,SETD2突变和CDKN2A缺失在控制大小后仍独立与侵袭性疾病、转移、更差生存和切除后复发相关。

研究设计与样本

  • 在来自TRACERx、TCGA和CAGEKID项目的1039例接受肾切除术的透明细胞肾细胞癌中评估突变(VHL、PBRM1、SETD2、BAP1和CDKN2A缺失)随肿瘤大小的分布。
  • 使用逻辑回归建模每种突变的存在与大小的关系。
  • 二次分析评估≤7 cm透明细胞肾细胞癌亚组中关键侵袭性突变(SETD2、BAP1和CDKN2A缺失)与转移、侵袭性疾病和总生存的关联,同时控制大小。
  • 另用≤7 cm局限性肿瘤亚组评估与肾切除术后复发的关联。

主要发现

  • 逻辑回归显示,肿瘤大小每增加1 cm与侵袭性突变SETD2、BAP1和CDKN2A缺失相关,OR分别为1.09、1.10和1.19(P<0.001)。
  • 肿瘤大小与PBRM1无显著关联(OR 1.02;P=0.23)。
  • VHL与大小每增加1 cm呈轻度负相关(OR 0.95;P=0.01)。
  • 在≤7 cm肿瘤中,控制肿瘤大小后,SETD2和CDKN2A缺失与转移性疾病相关,OR分别为3.86和3.84(P<0.05)。
  • CDKN2A缺失与更差总生存相关,HR为2.19(P=0.03);在≤7 cm局限性肿瘤中,SETD2与更差无复发生存相关(HR 2.00;P=0.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the distribution of key mutations across tumour sizes in clear-cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs. PATIENT AND METHODS: The distribution of mutations (VHL, PBRM1, SETD2, BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the Tracking Cancer Evolution (TRACERx), The Cancer Genome Atlas (TCGA) and the Cancer Genomics of the Kidney (CAGEKID) projects. Logistic regression was used to model the presence of each mutation against size. In our secondary analysis, we assessed a subset of ccRCCs ≤7 cm for associations of key aggressive mutations (SETD2, BAP1, and CDKN2A loss) with metastasis, invasive disease and overall survival, while controlling for size. A subset of localised tumours ≤7 cm was also used to assess associations with recurrence after nephrectomy. RESULTS: On logistic regression, each 1-cm increase in tumour size was associated with aggressive mutations, SETD2, BAP1, and CDKN2A loss, at odds ratios (ORs) of 1.09, 1.10 and 1.19 (P < 0.001), whereas no significant association was observed between tumour size and PBRM1 (OR 1.02; P = 0.23). VHL was mildly negatively associated with a 1-cm increase in size (OR 0.95; P = 0.01). Among tumours ≤7 cm, SETD2 and CDKN2A loss were associated with metastatic disease at ORs of 3.86 and 3.84 (P < 0.05) while controlling for tumour size. CDKN2A loss was associated with worse overall survival, with a hazard ratio (HR) of 2.19 (P = 0.03). Among localised tumours ≤7 cm, SETD2 was associated with worse recurrence-free survival (HR 2.00; P = 0.03). CONCLUSION: Large and small ccRCCs are genomically different. Aggressive mutations, namely, SETD2, BAP1, and CDKN2A loss, are rarely observed in small ccRCCs and are observed more frequently in larger tumours. However, when present in tumours ≤7 cm, SETD2 mutations and CDKN2A loss were still independently associated with invasive disease, metastasis, worse survival, and recurrence after resection, after controlling for size.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Monda SM, Carney BW, May AM, et al. Differences in mutations across tumour sizes in clear-cell renal cell carcinoma. BJU Int. 2024. PMID: 39263870. doi:10.1111/bju.16527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。